Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Clinical Trial Comparing Dose-intensified SBRT With Conventional Radiation Therapy for Spinal Metastases (DOSIS RCT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02800551
Recruitment Status : Recruiting
First Posted : June 15, 2016
Last Update Posted : November 2, 2018
Information provided by (Responsible Party):
University of Zurich

Brief Summary:
This study will compare pain (primary end-point) and local metastatic tumor control (secondary end-point) after dose-intensified image-guided fractionated stereotactic body radiation therapy (SBRT) for painful mass-type spinal metastases versus conventional radiation therapy.

Condition or disease Intervention/treatment Phase
Spinal Metastasis Radiation: dose-intensified image-guided SBRT using simultaneous integrated boost Radiation: External 3-dimensional conformal radiotherapy (3D-CRT) Phase 2

Detailed Description:

Rationale: Radiation therapy is an effective palliative treatment for painful spinal metastases. A sub-group of patients with mass-type spinal metastases, a factor associated with poor local metastasis control, require treatment optimization ensuring durable pain control and metastatic tumor control.

Proposed solution: To intensify (escalate) radiation dose using simultaneous integrated boost with image-guided hypofractionated SBRT for painful mass-type spinal metastases in a randomized controlled trial. Two experimental fractionation regimes will be tested in the study depending on presence or absence of epidural involvement. Dose intensification is expected to achieve long-term pain control and long-term palliation as well as long-term local metastatic tumor control without adding toxicity as compared to conventional fractionation regimes with conventional radiation therapy.

The study will be carried out as multinational, multicentre phase II clinical controlled trial enrolling patients with painful mass-type spinal metastases who are eligible for radiation therapy without surgery. This study additionally includes a prospective observational arm for patients not eligible for randomisation who are treated in analogy to arm A of the randomised arm.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 146 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Dose-intensified Image-guided Fractionated Stereotactic Body Radiation Therapy for Painful Spinal Metastases Versus Conventional Radiation Therapy: a Randomised Controlled Trial (DOSIS RCT)
Study Start Date : July 2016
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : July 2023

Arm Intervention/treatment
Experimental: SBRT (Arm A)

dose-intensified image-guided SBRT using simultaneous integrated boost:

  • in the case of no epidural involvement: 40 Gy and 20 Gy in 5 fractions to the high-dose and conventional-dose target volume, respectively.
  • In the case epidural involvement: 48.5 Gy and 30 Gy in 10 fractions to the high-dose and conventional-dose target volume, respectively.
Radiation: dose-intensified image-guided SBRT using simultaneous integrated boost
Active Comparator: Conventional Radiation Therapy (Arm B)

External 3-dimensional conformal radiotherapy (3D-CRT):

Homogeneous irradiation of the affected vertebra delivering either

  • 20 Gy in 5 fractions or
  • 30 Gy in 10 fractions.
Radiation: External 3-dimensional conformal radiotherapy (3D-CRT)
Experimental: SBRT (prospective observational)
Patients eligible for the prospective observational arm will be treated according to the investigational arm (arm A) of the randomised arm of the trial.
Radiation: dose-intensified image-guided SBRT using simultaneous integrated boost

Primary Outcome Measures :
  1. Pain response - improvement by ≥ 2 points on the pain Visual Analogue Scale at 6 months post-treatment at the treatment site [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Local metastasis control [ Time Frame: up to 2 years ]
    Local metastasis control is defined from the day of randomization to a day of local (at the site of the treated spinal metastasis) progression, i.e. local failure, determined on control MR images as a change in signal intensity or on CT images as increasing soft-tissue mass. Increased epidural disease or enlargement of paraspinal disease on control images will be documented as progression.

  2. Overall survival [ Time Frame: up to 2 years ]
    Overall survival is defined from the day of randomization to a day of death of any cause.

  3. Cancer-specific survival [ Time Frame: up to 2 years ]
    Cancer-specific survival is defined from the day of randomization to a day of death due to cancer progression.

  4. Quality-of-life (QoL) [ Time Frame: Day 1 and last day of treatment (usually day5 if Radiotherapy is delivered in 5 fractions, and day 12 if Radiotherapy is delivered in 10 fractions); months 1, 3, 6, 9, 12, 18 and 24 ]
    Quality-of-life (QoL) as measured by the EORTC QLQ-C15-PL, EORTC-BM22 and EQ-5D-5L patient reported questionnaires

  5. Epidural spinal cord compression [ Time Frame: up to 2 years ]
    Epidural spinal cord compression (ESCC) will be scored using Bilsky criteria.

  6. Acute and late toxicity [ Time Frame: Acute toxicity: up to 3 months; late toxicity: from 3 months up to 24 months ]
    Acute aund late toxicity will be assessed in accordance to NCI CTCEA version 4.03 criteria.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Established histological diagnosis of a malignant primary or metastatic tumor;
  • Histologically, radiologically or scintigraphically proven spinal metastasis;
  • Pain in the affected spinal region or free of pain under pain medication;
  • Age ≥18 years old;
  • Karnofsky performance status ≥60%;
  • Written informed consent.

Exclusion Criteria:

  • Modified Bauer Score < 2;
  • No-mass-type metastatic lesion, defined as a 3D space-occupying lesion visible on CT and/or MR;
  • "Radiosensitive" histology of the primary tumor, e.g., lymphoma, small-cell lung cancer, multiple myeloma, germ cell tumors;
  • Progressive neurological symptoms/deficit;
  • More than 3 affected vertebrae in one target site;
  • More than 2 treatment sites;
  • Spinal Instability Neoplastic Score (SINS) 13 - 18, i.e., unstable;
  • Unable to tolerate treatment (unable to lie flat and immobilized);
  • Previous radiotherapy of the region at the level of the affected vertebrae;
  • Previous radionuclide therapy within 30 days before stereotactic body radiation therapy;
  • Previous surgery (stabilization) of the affected vertebrae;
  • Contraindications for MR scanning, e.g., pacemakers;
  • Patients with allergy to contrast agents used in computer tomography (CT) and magnetic resonance (MR) imaging or patients who cannot be premedicated to use contrast agent;
  • Pregnant or lactating women;
  • Women of child bearing potential or sexually active males not willing to use effective contraception while on treatment and 3 months after the end of treatment;
  • Mental conditions rendering the patient unable to understand the nature, scope, and possible consequences of the study;
  • Patient unlikely to comply with protocol, i.e. uncooperative attitude, inability to return for follow-up visits, and unlikely to complete the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02800551

Layout table for location contacts
Contact: Indira Madani, Dr. +41 44 255 41 08
Contact: Antonia Schiess +41 44 255 41 08

Layout table for location information
UniversitätsSpital Zürich, Klinik für Radio-Onkologie Recruiting
Zürich, Switzerland, 8091
Sponsors and Collaborators
University of Zurich
Layout table for investigator information
Principal Investigator: Matthias Guckenberger, Prof. Dr. Universitätsspital Zürich
Layout table for additonal information
Responsible Party: University of Zurich Identifier: NCT02800551    
Other Study ID Numbers: DOSIS RCT
First Posted: June 15, 2016    Key Record Dates
Last Update Posted: November 2, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes